DekaBank Deutsche Girozentrale’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21M Hold
115,130
0.04% 312
2026
Q1
$21.4M Hold
115,130
0.04% 312
2025
Q4
$14M Hold
115,130
0.02% 389
2025
Q3
$14.7M Hold
115,130
0.02% 376
2025
Q2
$12.2M Sell
115,130
-178
-0.2% -$19.3K 0.02% 408
2025
Q1
$13.9M Buy
115,308
+178
+0.2% +$23.2K 0.03% 366
2024
Q4
$13.9M Hold
115,130
0.03% 384
2024
Q3
$12.6M Buy
115,130
+31,283
+37% +$3.43M 0.02% 413
2024
Q2
$8.91M Sell
83,847
-31,461
-27% -$3.46M 0.02% 472
2024
Q1
$13.9M Buy
115,308
+23,768
+26% +$2.91M 0.03% 383
2023
Q4
$11.2M Buy
91,540
+44,414
+94% +$5.54M 0.02% 403
2023
Q3
$6.16M Buy
47,126
+262
+0.6% +$34.9K 0.01% 503
2023
Q2
$5.82M Sell
46,864
-3,649
-7% -$491K 0.01% 524
2023
Q1
$7.25M Sell
50,513
-3,097
-6% -$458K 0.02% 472
2022
Q4
$8.44M Sell
53,610
-8,366
-13% -$1.23M 0.02% 430
2022
Q3
$8.21M Sell
61,976
-5,575
-8% -$848K 0.02% 422
2022
Q2
$10.4M Buy
67,551
+613
+0.9% +$94.4K 0.03% 378
2022
Q1
$10.6M Sell
66,938
-11,522
-15% -$1.67M 0.03% 416
2021
Q4
$10.3M Buy
78,460
+25,003
+47% +$3.29M 0.03% 412
2021
Q3
$6.91M Sell
53,457
-36,192
-40% -$5.47M 0.02% 460
2021
Q2
$15.8M Sell
89,649
-374
-0.4% -$64.8K 0.05% 299
2021
Q1
$14.9M Buy
90,023
+21,307
+31% +$3.51M 0.05% 283
2020
Q4
$11M Buy
68,716
+11,364
+20% +$1.69M 0.04% 311
2020
Q3
$7.94M Buy
57,352
+31,828
+125% +$3.95M 0.04% 315
2020
Q2
$2.78M Sell
25,524
-2,073
-8% -$229K 0.02% 417
2020
Q1
$2.76M Sell
27,597
-2,358
-8% -$305K 0.02% 368
2019
Q4
$4.46M Sell
29,955
-23,717
-44% -$3.23M 0.03% 359
2019
Q3
$6.86M Sell
53,672
-35,617
-40% -$4.77M 0.04% 310
2019
Q2
$12.4M Buy
89,289
+62,682
+236% +$8.42M 0.06% 292
2019
Q1
$4.61M Sell
26,607
-2,368
-8% -$309K 0.03% 439
2018
Q4
$3.55M Buy
28,975
+2,368
+9% +$351K 0.02% 426
2018
Q3
$4.61M Buy
26,607
+884
+3% +$152K 0.03% 445
2018
Q2
$4.51M Sell
25,723
-10,112
-28% -$1.65M 0.03% 421
2018
Q1
$5.36M Sell
35,835
-13,324
-27% -$1.95M 0.04% 379
2017
Q4
$7.3M Hold
49,159
0.06% 303
2017
Q3
$7.3M Sell
49,159
-10,398
-17% -$1.57M 0.06% 306
2017
Q2
$9.32M Sell
59,557
-126
-0.2% -$19.3K 0.07% 264
2017
Q1
$8.72M Buy
59,683
+4,527
+8% +$590K 0.08% 240
2016
Q4
$5.97M Buy
55,156
+662
+1% +$73.7K 0.06% 272
2016
Q3
$6.7M Buy
54,494
+15,858
+41% +$2.14M 0.07% 263
2016
Q2
$5.43M Buy
38,636
+320
+0.8% +$47.2K 0.06% 287
2016
Q1
$4.76M Sell
38,316
-3,150
-8% -$392K 0.06% 317
2015
Q4
$5.93M Buy
41,466
+390
+0.9% +$54K 0.07% 277
2015
Q3
$5.46M Buy
41,076
+2,576
+7% +$444K 0.07% 287
2015
Q2
$6.78M Buy
38,500
+870
+2% +$156K 0.08% 240
2015
Q1
$6.5M Sell
37,630
-3,100
-8% -$532K 0.08% 255
2014
Q4
$6.64M Buy
40,730
+3,330
+9% +$553K 0.08% 248
2014
Q3
$6M Buy
37,400
+830
+2% +$128K 0.08% 238
2014
Q2
$5.38M Buy
36,570
+250
+0.7% +$34.7K 0.08% 257
2014
Q1
$5.04M Buy
36,320
+3,170
+10% +$477K 0.08% 247
2013
Q4
$4.1M Sell
33,150
-4,004
-11% -$414K 0.07% 230
2013
Q3
$3.31M Buy
37,154
+2,450
+7% +$198K 0.06% 241
2013
Q2
$2.38M Buy
+34,704
New +$2.12M 0.05% 263

Other funds holding JAZZ

DekaBank Deutsche Girozentrale's JAZZ Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 115,130 shares worth $21M. The position accounts for 0.04% of the portfolio, ranked #312.

DekaBank Deutsche Girozentrale first reported a position in JAZZ in Q2 2013 and has held it in 53 quarters since. The position peaked at $21.4M in Q1 2026. 304 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • DekaBank Deutsche Girozentrale held 115,130 shares of Jazz Pharmaceuticals worth $21M as of Q2 2026.
  • DekaBank Deutsche Girozentrale left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up 0.04% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #312 holding.
  • DekaBank Deutsche Girozentrale first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • DekaBank Deutsche Girozentrale's Jazz Pharmaceuticals position peaked at $21.4M in Q1 2026.
  • 304 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.